Vericel to Present at the 2017 Cell & Gene Meeting on the Mesa
September 27 2017 - 8:00AM
Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded
autologous cell therapies for the treatment of patients with
serious diseases and conditions, today announced that Nick
Colangelo, president and CEO, will present at the Cell & Gene
Meeting on the Mesa at the Estancia La Jolla Hotel & Spa in La
Jolla, CA on Wednesday, October 4, 2017 at 5:45pm PDT.
Mr. Colangelo will also participate in the plenary session
“Implications of Commercialization: What Does Approval Mean?” at
9:15am PDT.
Organized by the Alliance for Regenerative Medicine (ARM) and
the Sanford Stem Cell Clinical Center at UC San Diego, the Cell
& Gene Meeting on the Mesa is a three-day conference featuring
three distinct parts: the program’s two-day Partnering Forum, a
Public Forum lecture and a full-day Scientific Symposium.
A live video webcast of all company presentations will be
available at http://www.meetingonthemesa.com/webcast and will also
be published on ARM’s website shortly after the event.
About Vericel CorporationVericel develops,
manufactures, and markets expanded autologous cell therapies for
the treatment of patients with serious diseases and conditions. The
company markets two cell therapy products in the United States.
Vericel is marketing MACI® (autologous cultured chondrocytes on
porcine collagen membrane), an autologous cellularized scaffold
product indicated for the repair of symptomatic, single or multiple
full-thickness cartilage defects of the knee with or without bone
involvement in adults. Vericel is also marketing Epicel® (cultured
epidermal autografts), a permanent skin replacement for the
treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. Vericel is
developing ixmyelocel-T, an autologous multicellular therapy
intended to treat advanced heart failure due to ischemic dilated
cardiomyopathy. For more information, please visit the company's
website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel
Corporation. © 2017 Vericel Corporation. All rights reserved.
Global Media Contacts:David SchullRusso
Partners LLC+1 212-845-4271 (office)+1 858-717-2310
(mobile)David.schull@russopartnersllc.com
Karen ChaseRusso Partners LLC+1 646-942-5627 (office)+1
917-547-0434 (mobile)Karen.chase@russopartnersllc.com
Investor Contacts: Chad RubinThe Trout
Groupcrubin@troutgroup.com+1 (646) 378-2947
Lee SternThe Trout Grouplstern@troutgroup.com+1 (646)
378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2023 to Sep 2024